Table of Content


1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Age Group
3.3. Snippet by Drug Type
3.4. Snippet by Route of Administration
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing the product approvals and clinical trails
4.1.1.2. The increasing geriatric population
4.2. Restraints
4.2.1.1. Lack of awareness about hyperuricemia diagnosis
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Primary*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Secondary
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Children *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
9. By Drug Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.1.2. Market Attractiveness Index, By Drug Type
9.2. Xanthine Oxidase Inhibitors *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Nonsteroidal Anti-Inflammatory Drugs
9.4. Corticosteroids
9.5. Others
10. By Route of Administration
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.1.2. Market Attractiveness Index, By Route of Administration
10.2. Oral*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Injectable
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail pharmacies
11.4. Online pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.9.1. Germany
12.3.9.2. UK
12.3.9.3. France
12.3.9.4. Italy
12.3.9.5. Spain
12.3.9.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Arthrosi Therapeutics, Inc*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Dr.Reddy’s
14.3. Urica Therapeutics, Inc
14.4. Zydus Lifesciences
14.5. Takeda Pharmaceutical Company Limited
14.6. Novartis AG
14.7. Hikma Pharmaceuticals Plc
14.8. Mylan N.V.
14.9. AstraZeneca Plc
14.10. Sun Pharmaceutical Industries Ltd
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us